Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Akari Therapeutics stock

Own Akari Therapeutics stock in just a few minutes.

Fact checked

Akari Therapeutics, Plc is a biotechnology business based in the US. Akari Therapeutics shares (AKTX) are listed on the NASDAQ and all prices are listed in US Dollars. Akari Therapeutics employs 10 staff and has a market cap (total outstanding shares value) of USD$123.1 million.

How to buy shares in Akari Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Akari Therapeutics. Find the stock by name or ticker symbol: AKTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Akari Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Akari Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Akari Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Akari Therapeutics share price

Use our graph to track the performance of AKTX stocks over time.

Akari Therapeutics shares at a glance

Information last updated 2021-02-23.
52-week rangeUSD$0.87 - USD$4.21
50-day moving average USD$2.7424
200-day moving average USD$1.9839
Wall St. target priceUSD$5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.874

Buy Akari Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Akari Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Akari Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -92.41%
Return on equity TTM -447.36%
Profit margin 0%
Book value $0.143
Market capitalisation USD$123.1 million

TTM: trailing 12 months

Shorting Akari Therapeutics shares

There are currently 158,031 Akari Therapeutics shares held short by investors – that's known as Akari Therapeutics's "short interest". This figure is 16.7% down from 189,747 last month.

There are a few different ways that this level of interest in shorting Akari Therapeutics shares can be evaluated.

Akari Therapeutics's "short interest ratio" (SIR)

Akari Therapeutics's "short interest ratio" (SIR) is the quantity of Akari Therapeutics shares currently shorted divided by the average quantity of Akari Therapeutics shares traded daily (recently around 405207.69230769). Akari Therapeutics's SIR currently stands at 0.39. In other words for every 100,000 Akari Therapeutics shares traded daily on the market, roughly 390 shares are currently held short.

However Akari Therapeutics's short interest can also be evaluated against the total number of Akari Therapeutics shares, or, against the total number of tradable Akari Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akari Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Akari Therapeutics shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Akari Therapeutics shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Akari Therapeutics.

Find out more about how you can short Akari Therapeutics stock.

Akari Therapeutics share dividends

We're not expecting Akari Therapeutics to pay a dividend over the next 12 months.

Have Akari Therapeutics's shares ever split?

Akari Therapeutics's shares were split on a 1:10 basis on 17 September 2015. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Akari Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Akari Therapeutics shares which in turn could have impacted Akari Therapeutics's share price.

Akari Therapeutics share price volatility

Over the last 12 months, Akari Therapeutics's shares have ranged in value from as little as $0.87 up to $4.21. A popular way to gauge a stock's volatility is its "beta".

AKTX.US volatility(beta: 1.44)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akari Therapeutics's is 1.4424. This would suggest that Akari Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Akari Therapeutics overview

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site